Selective laser trabeculoplasty (SLT) is now one of the most important and most advanced laser treatments for lowering intraocular pressure in glaucoma. It improves the outflow of aqueous humour in the so-called trabecular meshwork, a fine structure in the chamber angle between the cornea and the iris. Improved outflow lowers intraocular pressure—the key risk factor for damage to the optic nerve.

Unlike earlier laser methods such as argon laser trabeculoplasty (LTP/ALT), SLT uses very short, selectively acting pulses. These target pigmented cells specifically without causing thermal damage to the surrounding tissue. This makes SLT particularly gentle, repeatable, and tissue-sparing. The treatment takes only a few minutes, involves minimal discomfort, and is performed on an outpatient basis.

The European Glaucoma Society (EGS) now officially lists SLT as a first-line therapy—that is, an equivalent initial treatment alongside prostaglandin eye drops. Studies show that SLT can achieve a comparable reduction in pressure, but without the daily requirements and potential side effects of drop therapy. For many patients, it is therefore an attractive, sustainable, and medication-free treatment option.

The effect of SLT often lasts for several years. If intraocular pressure rises again later, the treatment can be repeated if the initial situation is suitable. Even if eye drops are already being used, SLT can complement the treatment plan or make it possible to reduce drops.

SLT is particularly suitable for patients who want a simple, gentle, and everyday-friendly treatment—but also for those who do not tolerate drops well or have difficulty using them regularly.

At Eyeside, we offer SLT directly in our practice and will advise you individually on whether this modern laser treatment is the best option for your type of glaucoma.